glycyl-glycyl-cysteine has been researched along with copper gluconate in 1 studies
Studies (glycyl-glycyl-cysteine) | Trials (glycyl-glycyl-cysteine) | Recent Studies (post-2010) (glycyl-glycyl-cysteine) | Studies (copper gluconate) | Trials (copper gluconate) | Recent Studies (post-2010) (copper gluconate) |
---|---|---|---|---|---|
7 | 0 | 2 | 3,657 | 233 | 653 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Altai, M; Honarvar, H; Larsson, E; Löfblom, J; Lubberink, M; Orlova, A; Sandström, M; Ståhl, S; Strand, J; Strand, SE; Tolmachev, V; Varasteh, Z; Wållberg, H | 1 |
1 other study(ies) available for glycyl-glycyl-cysteine and copper gluconate
Article | Year |
---|---|
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Topics: Animals; Antibodies; Cell Line, Tumor; Chelating Agents; Drug Evaluation, Preclinical; Female; Gluconates; Humans; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Peptides; Radiation Dosage; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptor, ErbB-2; Rhenium; Xenograft Model Antitumor Assays | 2014 |